RSRubén Silva-Tinoco

Rubén Silva-Tinoco

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rubén Silva-Tinoco has a total of 174 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prevalence and Population Burden of Operational Cardiovascular-Kidney-Metabolic Syndrome Stages Among Mexican Adults: A Nationally Representative Cross-sectional Study

    by Rubén Silva-Tinoco, Alejandro Avalos-Bracho, Alinne A. Rivas-Alarcón, Aldo Ferreira-Hermosillo, Daniel Elías-López, Hugo E. Chávez-Chávez, Arturo Orea-Tejeda, Humberto Salazar-Zaragoza

  • Open Access

    Integrative Monitoring of Hypertension Care Using Routinely Collected Clinical Data in Mexico’s Emerging Federalised Public Health Care Provider

    by Rubén Silva-Tinoco, Alejandro Avalos-Bracho, Gabriel Gutiérrez-Morales, Erick Vladimir Martínez-De la Cruz, Elena Monserrat Licona-León, María Fernanda Bernal-Ceballos

    Background: Health information systems are a cornerstone for assessing health system performance, particularly for leading conditions contributing to disease burden, such as hypertension, making effective monitoring indispensable. In October 2023, Mexico initiated the federalisation of public health services for the population without social security, creating an integrated national public health care provider and increasing the need for system-level monitoring tools capable of supporting longitudinal assessment across heterogeneous settings. Objective: To describe the development and early application of an integrative monitoring platform using routinely collected clinical data to support system-level oversight of hypertension care within Mexico’s federalised public health care provider. Design: Descriptive health services research study based on secondary analysis of routinely collected clinical data. Methods: An integrative monitoring platform was developed to organise data into a structured indicator framework covering four domains: care engagement and continuity; clinical care processes; intermediate clinical outcomes; and case-mix and clinical complexity. The platform enables longitudinal and subnational analyses across selected indicators presented as illustrative use cases. Institutional reach was assessed using an overall monitoring period from January 2024 to September 2025, while clinical process and intermediate outcome indicators, including blood pressure control, were calculated within a predefined active six-month monitoring cohort using the September 2025 reporting date. Results: From January 2024 to September 2025, a total of 486,044 individuals received hypertension-related care within primary care services across participating states. The active six-month cohort included 322,661 individuals, with 67.2% (95% CI, 67.04–67.37) achieving blood pressure control (<140/90 mmHg), and 36.8% (95% CI, 36.62–36.96) achieving strict control (<130/80 mmHg). For those with sub-optimal control, 63% had timely clinical follow-up and 48% underwent treatment intensification. A high proportion of individuals presented high risk features including obesity (36.4%; 95%CI, 36.2–36.5), diabetes (48.7%; 95%CI, 48.5–48.8) or high cardiovascular risk characteristics (81.7%, 95%IC, 81.5–81.8). Conclusion: Transforming routinely collected clinical data into an integrative monitoring platform is feasible within a newly federalised public health care provider. Routine monitoring of relevant indicators across multiple dimensions of care provides a structured basis for system-level oversight, longitudinal assessment, data-informed decision-making, and continuous learning within large public service delivery systems.

  • Open Access

    Integrating MASLD detection into diabetes care in primary care settings in Mexico: A cascade analysis

    by Rubén Silva-Tinoco, Erick Vladimir Martínez-De la Cruz, Ana Galíndez-Fuentes, Berenice Cabrera-Victoria, Erick Villa-Mejía, Ricardo Ulises Macías-Rodríguez, Alejandro Avalos-Bracho, María Fernanda Bernal-Ceballos


  • Open Access

    Integrated Cardiovascular–Kidney–Metabolic Disease Burden in Mexico: Trends from 2000 to 2023 and Projections to 2050

    by Rubén Silva-Tinoco, María Fernanda Bernal-Ceballos, Alejandro Avalos-Bracho, Lilia Castillo-Martínez, Vladimir Martínez-De la Cruz, José Manuel Arreola-Guerra, Daniel Sierra Lara-Martínez, Paloma Almeda-Valdes

    Background: Cardiovascular–kidney–metabolic (CKM)‑related diseases are interconnected, yet their collective burden in Mexico remains unquantified. Objective(s): To quantify the magnitude, composition, temporal trends, geographic divergence, and projected trajectory of CKM‑related disease burden in Mexico. Methods: We analyzed Global Burden of Disease 2023 estimates of CKM‑related burden among Mexican adults aged 20 years or older; standard all‑age age‑standardized rates were used for comparisons with Latin America and the Caribbean and globally. Mutually exclusive causes were grouped into cardiovascular, kidney, type 2 diabetes, and metabolic dysfunction‑associated steatotic liver disease domains. We quantified disability‑adjusted life‑years (DALYs) during 2000–2023 and used 1990–2023 time series to project absolute burden and age‑standardized rates to 2050. Findings: CKM‑related DALYs increased from 3.82 million in 2000 to 8.71 million in 2023 (128%), and their share of all‑cause DALYs rose from 20.2% to 25.0%. In 2023, premature mortality accounted for 76.8% of the burden; cardiovascular disease and type 2 diabetes together accounted for 88.4%, with diabetes predominating among adults aged 40–64 years. Mexico’s age‑standardized DALY rate increased by 2.9% during 2000–2023, whereas rates declined by 16.1% in Latin America and the Caribbean and by 24.1% globally. Absolute DALYs are projected to reach 21.40 million by 2050 (95% prediction interval 19.27–23.77), while the age‑standardized rate remains broadly unchanged. Conclusions: Mexico has diverged from declining regional and global trends in age‑standardized CKM‑related burden. Persistent premature mortality, substantial diabetes burden during working age, and projected growth in absolute health loss support accelerated, coordinated public health and health‑system action across the CKM continuum.

  • Open Access

    Uncontrolled Hypertension in Cardio‐Renal‐Metabolic Diseases: Real‐World Insights on Patient Profiles and Management Patterns From iCaReMe Global Registry

    by Kamlesh Khunti, Mustafa Arici, Carol Pollock, Chien-Ning Huang, Rubén Silva-Tinoco, Adel A. El Sayed, Esteban Coto, Karim Salama, Hardik Vasnawala, Ahmed Hadaoui

    Background: Hypertension (HTN) is a leading risk factor for cardiovascular (CV) and renal morbidity and mortality, yet blood pressure (BP) control remains suboptimal worldwide. Understanding management patterns, especially among patients with coexisting Type 2 diabetes mellitus (T2DM), chronic kidney diseases (CKDs), or heart failure (HF), and assessing uncontrolled HTN burden across diverse health systems are critical to inform guideline‐concordant strategies to improve care. Methods: Cross‐sectional analysis includes participants with HTN, with or without comorbid T2DM, CKD, or HF enrolled in iCaReMe Global Registry across 29 countries. Demographic and clinical characteristics, antihypertensive treatment patterns, prevalence of uncontrolled HTN (defined as SBP ≥ 130 mmHg or DBP ≥ 80 mmHg), and its associated factors were assessed. Results: Among 23,063 participants, comorbidities included T2DM (71.4%), CKD (38.2%), and HF (14.6%). Key CV risk factors were family history of CV disease (34.3%), obesity (40.5%), and dyslipidemia (51.0%). Echocardiography (available in 28.6%) revealed left ventricular hypertrophy (LVH) in 30.6% and diastolic dysfunction in 42.4%. Overall, 88.7% were prescribed antihypertensive drugs: renin–angiotensin system (RAS) blockers (76.6%), calcium channel blockers (CCBs, 42.0%), beta‐blockers (41.4%), diuretics (23.7%), with a majority (62.3%) on combination regimens. Uncontrolled HTN was prevalent in 75.4%, who were younger (59.8 vs 61.8 years) and exhibited higher burden of obesity (42.5% vs 34.6%), CKD (39.3% vs 33.1%), LVH (32.9% vs 24.8%), and treated less intensively with antihypertensives (60.2% vs 88.7%) and combinations (46.2% vs 61.8%) when compared to the controlled HTN group. Multivariate analysis confirmed independent association of non‐use of RAS blockers/CCB/diuretics combinations (dual/triple therapy), obesity, and comorbid CKD, with uncontrolled HTN (OR [95% CI], 2.8 [2.44–3.18]/2.3 [1.66–3.16], 1.5 [1.38–1.65], and 1.4 [1.27–1.53], respectively, p < 0.0001). Conclusion: This study uncovers alarming rates of uncontrolled HTN in real‐world settings, exacerbated by comorbid T2DM/CKD/HF, underscoring the need to identify HTN management gaps and tailor innovative strategies to mitigate CV risk. Trial Registration: ClinicalTrials.gov identifier: NCT03549754

  • Open Access

    Exploring prediabetes remission in public primary care in Mexico: A cascade analysis

    by Rubén Silva-Tinoco, Lilia Castillo-Martínez, Alejandra Pérez-Galván, Viridiana de la Torre-Saldaña, Eileen Guzmán-Olvera, Christian Hinojosa-Segura, Alejandro Avalos-Bracho


  • Open Access

    External validation of a minimal-resource model to predict reduced estimated glomerular filtration rate in people with type 2 diabetes without diagnosis of chronic kidney disease in Mexico: a comparison between country-level and regional performance

    by Camilla Sammut-Powell, Rose Sisk, Ruben Silva-Tinoco, Gustavo de la Pena, Paloma Almeda-Valdes, Sonia Citlali Juarez Comboni, Susana Goncalves, Rory Cameron

    Background: Patients with type 2 diabetes are at an increased risk of chronic kidney disease (CKD) hence it is recommended that they receive annual CKD screening. The huge burden of diabetes in Mexico and limited screening resource mean that CKD screening is underperformed. Consequently, patients often have a late diagnosis of CKD. A regional minimal-resource model to support risk-tailored CKD screening in patients with type 2 diabetes has been developed and globally validated. However, population heath and care services between countries within a region are expected to differ. The aim of this study was to evaluate the performance of the model within Mexico and compare this with the performance demonstrated within the Americas in the global validation.Methods: We performed a retrospective observational study with data from primary care (Clinic Specialized in Diabetes Management in Mexico City), tertiary care (Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán) and the Mexican national survey of health and nutrition (ENSANUT-MC 2016). We applied the minimal-resource model across the datasets and evaluated model performance metrics, with the primary interest in the sensitivity and increase in the positive predictive value (PPV) compared to a screen-everyone approach.Results: The model was evaluated on 2510 patients from Mexico (primary care: 1358, tertiary care: 735, ENSANUT-MC: 417). Across the Mexico data, the sensitivity was 0.730 (95% CI: 0.689 – 0.779) and the relative increase in PPV was 61.0% (95% CI: 52.1% - 70.8%). These were not statistically different to the regional performance metrics for the Americas (sensitivity: p=0.964; relative improvement: p=0.132), however considerable variability was observed across the data sources.Conclusion: The minimal-resource model performs consistently in a representative Mexican population sample compared with the Americas regional performance. In primary care settings where screening is underperformed and access to laboratory testing is limited, the model can act as a risk-tailored CKD screening solution, directing screening resources to patients who are at highest risk.


  • Impact of a multicomponent integrated care delivery program on diabetes care goals achievement: a primary care quality improvement initiative

    by Ruben Silva-Tinoco, Teresa Cuatecontzi-Xochitiotzi, Lilia Castillo-Martínez, Viridiana de la Torre-Saldaña, Eileen Guzman-Olvera, Fernanda Bernal-Ceballos


  • Adherence to antidiabetic treatment in primary health care in individuals with type 2 diabetes. A survey including socio-demographic, patient related and clinical factors

    by Ruben Silva-Tinoco, Teresa Cuatecontzi-Xochitiotzi, Fernanda Bernal-Ceballos, Viridiana de la Torre-Saldaña, Ana Galindez-Fuentes, Lilia Castillo-Martínez